Cancer metastasis reviews最新文献

Optimal choice of different neoadjuvant chemoradiotherapies for locally advanced rectal cancer: systematic review and network meta-analysis. 局部晚期直肠癌不同新辅助放化疗的最佳选择：系统评价和网络荟萃分析。

Cancer metastasis reviews Pub Date : 2025-07-23 DOI: 10.1007/s10555-025-10279-x

Lian Liu, Guangyu Yao, Junhao Yang, Yaxuan Miao, Yi Ba, Xicheng Wang

{"title":"Optimal choice of different neoadjuvant chemoradiotherapies for locally advanced rectal cancer: systematic review and network meta-analysis.","authors":"Lian Liu, Guangyu Yao, Junhao Yang, Yaxuan Miao, Yi Ba, Xicheng Wang","doi":"10.1007/s10555-025-10279-x","DOIUrl":"10.1007/s10555-025-10279-x","url":null,"abstract":"The objective of this study is to compare the pathological complete response (pCR) and survival rates of different neoadjuvant chemoradiotherapy modalities (NACRT) for locally advanced rectal cancer, which is defined as rectal cancer with T3-4/N + and without distant metastasis. We searched PubMed, Web of Science, Cochrane Central Register of Controlled Trials (CENTRAL), Embase, the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), and the Chinese Society of Clinical Oncology (CSCO) for randomized controlled trials (RCTs) and late-breaking abstracts on NACRT in locally advanced rectal cancer (LARC) patients with microsatellite stable (MSS) from inception to December 2024. Eighteen articles including 11658 MSS LARC patients were included: nine articles compared concurrent oxaliplatin or irinotecan with standard chemoradiotherapy, six articles conducted total neoadjuvant chemotherapy (cTNT), and three articles integrated immunotherapy (iTNT) as the NACRT regimen. CapOX cTNT modality ranked first to achieve the best pCR. The consolidation of two cycles of CapOX/FOLFOX cTNT ranked first in achieving the best 5-year overall survival (OS) rate. The consolidation of six cycles of FOLFOX cTNT ranked first in achieving the best 5-year disease-free survival (DFS) rate. Evidence from this network meta-analysis suggests that cTNT regimens, including CapOX cTNT and mFOLFIRINOX cTNT as induction regimens, have significant benefits in achieving the best pCR rate in MSS LARC patients. According to our network analysis, iTNT was not as beneficial as cTNT in achieving the best pCR. Consolidation of cTNT has the advantage of achieving long-term survival. Adverse events (AEs) reported for most iTNT modalities appear manageable.","PeriodicalId":520582,"journal":{"name":"Cancer metastasis reviews","volume":"44 3","pages":"62"},"PeriodicalIF":0.0,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144693053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Astrocyte involvement in brain metastasis: from biological mechanisms to therapeutic strategies. 星形胶质细胞参与脑转移：从生物学机制到治疗策略。

Cancer metastasis reviews Pub Date : 2025-07-15 DOI: 10.1007/s10555-025-10276-0

Teng Zhou, Yuxin Yan, Mingxi Lin, Cheng Zeng, Xinhui Mao, Yifei Zhu, Jinlu Han, Dou-Dou Li, Jian Zhang

{"title":"Astrocyte involvement in brain metastasis: from biological mechanisms to therapeutic strategies.","authors":"Teng Zhou, Yuxin Yan, Mingxi Lin, Cheng Zeng, Xinhui Mao, Yifei Zhu, Jinlu Han, Dou-Dou Li, Jian Zhang","doi":"10.1007/s10555-025-10276-0","DOIUrl":"10.1007/s10555-025-10276-0","url":null,"abstract":"BrMs represent a significant clinical challenge due to its high incidence, complex biology, and poor prognosis. Astrocytes, the predominant glial cells in the central nervous system, are increasingly recognized for their central role in shaping the brain microenvironment and driving the progression of brain metastases. This review highlights the multifaceted contributions of astrocytes to the metastatic cascade, including their involvement in tumor cell invasion, modulation of the blood-brain barrier, and establishment of a pro-metastatic niche. Astrocytes interact with tumor cells through various mechanisms, such as forming gap junctions, secreting factors that enhance tumor survival, and supporting immune evasion. These interactions promote tumor growth and protect metastatic cells from chemotherapy and radiotherapy, complicating current treatment strategies. Furthermore, astrocytes help reshape the brain microenvironment to support tumor adaptation and expansion, making them critical players in both the early and late stages of metastasis. Emerging therapeutic approaches are focused on disrupting astrocyte-tumor interactions, with strategies targeting astrocyte-driven communication pathways, immune modulation, and metabolic support systems. Nanotechnology and precision medicine also offer novel opportunities to improve drug delivery across BBB and directly target the astrocyte-tumor axis. This review underscores the importance of further research to fully understand the role of astrocytes in brain metastasis and develop therapies that leverage this knowledge to improve patient outcomes.","PeriodicalId":520582,"journal":{"name":"Cancer metastasis reviews","volume":"44 3","pages":"60"},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12263814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144645177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Metastasis-promoting functions of myeloid cells. 骨髓细胞促进转移的功能。

Cancer metastasis reviews Pub Date : 2025-07-15 DOI: 10.1007/s10555-025-10278-y

Sergei Kusmartsev

{"title":"Metastasis-promoting functions of myeloid cells.","authors":"Sergei Kusmartsev","doi":"10.1007/s10555-025-10278-y","DOIUrl":"10.1007/s10555-025-10278-y","url":null,"abstract":"The tumor metastatic dissemination and colonization is a highly complex, multi-step process that requires cooperation between cancer and host cells. Among these, cells of myeloid lineage mobilized from the bone marrow are crucial in facilitating tumor metastatic outgrowth. Recent studies indicate that myeloid cells of bone marrow origin, including myeloid-derived suppressor cells (MDSCs), macrophages, and progenitor cells, promote distant metastasis through immunological and non-immunological mechanisms. These cells are key contributors to creating an immunosuppressive microenvironment in the invaded tissue and draining lymph nodes, protecting metastatic cells from immunosurveillance, and promoting resistance to immunotherapy. Furthermore, the myeloid cells mediate the remodeling of the extracellular matrix (ECM) in a metastatic niche via enzymes MMP9 and Hyal2, stimulating angiogenesis and establishing a metastasis-permissive microenvironment. This review describes recent findings demonstrating the metastasis-promoting functions of recruited marrow-derived myeloid cells throughout metastatic colonization and suggests new therapeutic avenues.","PeriodicalId":520582,"journal":{"name":"Cancer metastasis reviews","volume":"44 3","pages":"61"},"PeriodicalIF":0.0,"publicationDate":"2025-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12263759/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144639560","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CRISPR screening approaches in breast cancer research. 乳腺癌研究中的CRISPR筛选方法。

Cancer metastasis reviews Pub Date : 2025-07-12 DOI: 10.1007/s10555-025-10275-1

Mark Samuels, Simoni Besta, Andrea Lauer Betrán, Reza Shirazi Nia, Xiaohong Xie, Xidong Gu, Qijin Shu, Georgios Giamas

{"title":"CRISPR screening approaches in breast cancer research.","authors":"Mark Samuels, Simoni Besta, Andrea Lauer Betrán, Reza Shirazi Nia, Xiaohong Xie, Xidong Gu, Qijin Shu, Georgios Giamas","doi":"10.1007/s10555-025-10275-1","DOIUrl":"10.1007/s10555-025-10275-1","url":null,"abstract":"The emergence of CRISPR-Cas9 technology has transformed functional genomics, offering unmatched opportunities to dissect and understand biological pathways and identify novel therapeutic targets in cancer. Breast cancer is a complex, heterogeneous disease and remains a major cause of morbidity and mortality in women, particularly when diagnosed at advanced or metastatic stages where effective treatments are limited. High-throughput CRISPR screening is undoubtedly a powerful tool to discover novel drug targets, uncover synthetic lethal interactions, and identify vulnerabilities in cancer. This review focuses on advances in our understanding of breast cancer developed through CRISPR-based screening technology, particularly in identifying drivers of breast cancer progression, growth, and metastasis, as well as in identifying potential new therapeutic targets and combination therapies. We discuss recent discoveries, current challenges, and limitations of this approach and explore how advancements in CRISPR technology could have a profound impact on the future of breast cancer treatment.","PeriodicalId":520582,"journal":{"name":"Cancer metastasis reviews","volume":"44 3","pages":"59"},"PeriodicalIF":0.0,"publicationDate":"2025-07-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12255600/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144621695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Tissue-agnostic biomarkers in solid tumors: current approvals and emerging candidates. 实体肿瘤中与组织无关的生物标志物：目前的批准和新出现的候选物。

Cancer metastasis reviews Pub Date : 2025-06-27 DOI: 10.1007/s10555-025-10274-2

Jinah Kim, Hye Sung Kim, Myungwoo Nam, Young Kwang Chae

{"title":"Tissue-agnostic biomarkers in solid tumors: current approvals and emerging candidates.","authors":"Jinah Kim, Hye Sung Kim, Myungwoo Nam, Young Kwang Chae","doi":"10.1007/s10555-025-10274-2","DOIUrl":"10.1007/s10555-025-10274-2","url":null,"abstract":"The landscape of cancer treatment has shifted from histology-specific to tissue-agnostic approaches, targeting molecular alterations regardless of tumor origin. Currently, six pan-cancer biomarkers-NTRK, BRAF V600E, RET, HER2-positive, MSI-high, and TMB-high-along with nine molecularly targeted therapies have expanded treatment options across diverse malignancies. This review examines each biomarker's molecular basis, prevalence across tumor types, and corresponding FDA-approved therapies. Additionally, emerging candidates-including FGFR, ALK, MET, ROS1, NRG1, PIK3CA, AKT, KRAS G12C, HER2 mutations, HER2-low/ultralow, B7-H3, and tumor-infiltrating lymphocytes (TILs)-are explored. While these biomarkers represent a paradigm shift in oncology, their integration into clinical practice requires overcoming challenges related to tumor heterogeneity and lineage-specific molecular dependencies. Future research should focus on identifying novel biomarkers, optimizing treatment strategies through multiomic analyses, and leveraging innovative clinical trial designs to advance precision oncology. In particular, further investigation into TILs as a predictive biomarker for immunotherapy is warranted, given their distinct immunophenotypic features and prognostic significance in shaping treatment responses across cancer types.","PeriodicalId":520582,"journal":{"name":"Cancer metastasis reviews","volume":"44 3","pages":"58"},"PeriodicalIF":0.0,"publicationDate":"2025-06-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12204918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144510295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prospects and limitations of NK cell adoptive therapy in clinical applications. NK细胞过继疗法在临床应用中的前景与局限性。

Cancer metastasis reviews Pub Date : 2025-06-25 DOI: 10.1007/s10555-025-10273-3

Yamin Deng, Chen Wu, Jintong Na, Jing Tang, Simin Qin, Zhiyong Zhang, Liping Zhong

引用次数: 0

Shaping the battlefield: EGFR and KRAS tumor mutations' role on the immune microenvironment and immunotherapy responses in lung cancer. 塑造战场：EGFR和KRAS肿瘤突变在肺癌免疫微环境和免疫治疗反应中的作用

Cancer metastasis reviews Pub Date : 2025-06-17 DOI: 10.1007/s10555-025-10272-4

Bassel Alsaed, Nina Bobik, Hanna Laitinen, Tanvi Nandikonda, Ilkka Ilonen, Heidi M Haikala

{"title":"Shaping the battlefield: EGFR and KRAS tumor mutations' role on the immune microenvironment and immunotherapy responses in lung cancer.","authors":"Bassel Alsaed, Nina Bobik, Hanna Laitinen, Tanvi Nandikonda, Ilkka Ilonen, Heidi M Haikala","doi":"10.1007/s10555-025-10272-4","DOIUrl":"10.1007/s10555-025-10272-4","url":null,"abstract":"The two most common and mutually exclusive driver mutations in non-small cell lung cancer affect EGFR and KRAS oncogenes. While EGFR mutations typically arise in non-smokers and are correlated with non-inflamed tumor microenvironment, KRAS mutations are associated with tobacco smoking, high mutational burden, and immunologically more active tumors. Consequently, current cancer immunotherapies have failed in patients with EGFR mutations, while patients with KRAS mutations have more favorable outcomes. The distinctive properties of the tumor immune microenvironment can partly explain the differences in the treatment outcomes. Besides the undeniable role of T lymphocytes, other immune cell types, cancer-associated fibroblasts, immunomodulatory cytokines, and angiogenesis are emerging as important players in these tumors. This article summarizes the current knowledge about the impact of EGFR versus KRAS mutations, among other mutations, on the tumor microenvironment and immunotherapy responses in lung cancer, highlighting the possible clinical implications for present and upcoming immunotherapy regiments, as well as emphasizing the gaps in the current knowledge that should be further investigated.","PeriodicalId":520582,"journal":{"name":"Cancer metastasis reviews","volume":"44 3","pages":"56"},"PeriodicalIF":0.0,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12170712/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144311186","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of PLK4 inhibition in cancer therapy. PLK4抑制在癌症治疗中的作用。

Cancer metastasis reviews Pub Date : 2025-06-13 DOI: 10.1007/s10555-025-10271-5

Kishore Banik, Thomas J Hayman

引用次数: 0

Opioid use and the risk of cancer incidence and mortality: a systematic review. 阿片类药物使用与癌症发病率和死亡率的风险：一项系统综述。

Cancer metastasis reviews Pub Date : 2025-06-11 DOI: 10.1007/s10555-025-10268-0

Shakti Shrestha, Holly Foot, Mahdi Sheikh, Marie-Odile Parat, Adam La Caze

{"title":"Opioid use and the risk of cancer incidence and mortality: a systematic review.","authors":"Shakti Shrestha, Holly Foot, Mahdi Sheikh, Marie-Odile Parat, Adam La Caze","doi":"10.1007/s10555-025-10268-0","DOIUrl":"10.1007/s10555-025-10268-0","url":null,"abstract":"There is abundant but discrepant scientific literature reporting an effect of opioids on the course of cancer. The International Agency for Research on Cancer monographs recently classified opium consumption as carcinogenic to humans in certain organs, raising concerns this may be due at least in part to the alkaloids opium contains (such as morphine and codeine). This systematic review investigated whether opioid exposure among cancer-free individuals is independently associated with the risk of future cancer incidence or cancer mortality. An electronic database search was conducted in PubMed, EMBASE, Web of Science, PsycINFO, International Pharmaceutical Abstracts, CINAHL and Scopus. Studies were included if they provided a statistical estimate of cancer mortality, cancer incidence, or cancer risk following opioid exposure. Study quality was assessed using the Newcastle-Ottawa Scale. Study characteristics and outcomes were extracted and analysed in a descriptive narrative synthesis. There were 27 studies that met the inclusion criteria, representing a total of 4,542,745 participants. Twelve of the 27 were rated as high quality according to the Newcastle-Ottawa Scale. The observed data is consistent with a small increase in the risk of cancer incidence or cancer mortality following opioid exposure, particularly in a subset of organs. There is, however, considerable uncertainty in the evidence given the substantial risk of bias in estimating the overall effect of opioid exposure on cancer outcomes in these studies. This review synthesises studies reporting cancer risk following opioid exposure and identifies the key methodological factors influencing ongoing uncertainty estimating the true effect. Rigorous epidemiological studies employing specific methods to minimize bias are warranted.","PeriodicalId":520582,"journal":{"name":"Cancer metastasis reviews","volume":"44 2","pages":"54"},"PeriodicalIF":0.0,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12159095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The invadosome of stem-like cancer cells: metastasis machinery and targetable vulnerability. 干细胞样癌细胞的侵袭体：转移机制和靶向易损性。

Cancer metastasis reviews Pub Date : 2025-06-04 DOI: 10.1007/s10555-025-10270-6

Kelvin K Tsai

{"title":"The invadosome of stem-like cancer cells: metastasis machinery and targetable vulnerability.","authors":"Kelvin K Tsai","doi":"10.1007/s10555-025-10270-6","DOIUrl":"10.1007/s10555-025-10270-6","url":null,"abstract":"Despite recent advances in targeted and immuno-therapy, metastasis still kills most cancer patients. Overcoming cancer metastasis requires a leap forward in understanding its molecular underpinnings to identify breakthrough therapeutic targets and strategies. A growing body of evidence suggests that specific subsets of cancer cells, which exhibit stem-like properties and are referred to as cancer stem cells (CSCs), are the primary drivers of cancer metastasis. How CSCs contribute to the multistep process of invasion and metastasis remains incompletely understood. Invadosomes are dynamic actin-based cellular protrusions that mediate cell invasion and pericellular proteolysis. Recent data have highlighted the highly proficient ability of CSCs to generate invadosomes, facilitating their local invasiveness, intravasation, extravasation, and metastatic colonization. This up-to-date and focused review describes the recent progress in characterizing invadosomes in embryonic cells during development and in CSCs during cancer metastasis. We summarize the molecular processes that regulate the invadosomes of CSCs. We discuss the molecules associated with the invadosome of CSCs and highlight their correlation with cancer metastasis in patients. We propose targeting the invadosomes of CSCs as a novel strategy to overcome cancer invasiveness and metastasis. This review highlights the emerging role of invadosomes in CSCs and provides a new perspective on pathobiology and cancer metastasis treatment.","PeriodicalId":520582,"journal":{"name":"Cancer metastasis reviews","volume":"44 2","pages":"53"},"PeriodicalIF":0.0,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144218533","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0